Protalix BioTherapeutics (PLX) Stock: Buy, Sell, or Hold?
PLX - Protalix BioTherapeutics, Inc. Common Stock
$2.55
-0.02 (-0.78%)
▼
5d:
-2.67%
30d:
-7.27%
90d:
+6.25%
HOLD
MODERATE Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 12, 2026
19d
Get Alerted When PLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PLX trades at premium valuation expecting 12.8% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: PLX trades at premium valuation expecting 12.8% growth. Hold existing positions but don't chase. Wait for better entry.
In-depth Analysis How we analyze
Valuation Analysis: PLX is currently trading at $2.55, which is considered oversold relative to its 30-day fair value range of $2.62 to $2.77. From a valuation perspective, the stock is trading at a premium (Forward PE: 51.0) compared to its historical average (35.5). At these levels, the market is pricing in 12.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PLX is in a strong uptrend. The price is currently testing key support at $2.50. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PLX scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (17th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.00 (+331.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PLX is in a strong uptrend. The price is currently testing key support at $2.50. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PLX scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (17th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.00 (+331.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.62 -
$2.77
Company Quality Score
54/100
(HOLD)
Options IV Signal
17th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
65.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 17th percentile)
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 331.4% below Wall St target ($11.00)
- NEUTRAL: PE elevated vs history but 12.8% growth expectation is conservative given 2241% recent growth
Trading Range Analysis
30-Day Trading Range
$2.62 -
$2.77
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.40
(15.7%)
Support & Resistance Levels
Support Level
$2.50
Resistance Level
$2.80
Current Trend
Strong Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
51.00
Wall Street Target
$11.00
(+331.4%)
Revenue Growth (YoY)
27.1%
Earnings Growth (YoY)
2241.1%
Profit Margin
23.5%
Valuation Premium vs History
+12.8% premium
PE vs Historical
51.0 vs 35.5
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+12.8%
(market-implied from PE analysis)
1-Year Target
$2.88
(+13%)
2-Year Target
$3.24
(+27%)
3-Year Target
$3.66
(+44%)
3-Yr Target (if PE normalizes)
(PE: 51→36)
PE COMPRESSION
$2.55
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 51.0, Growth: -79.2%)
$1.86
(+-27%)
Base:
(SPY PE: 19.9, Growth: -79.2%)
$0.72
(-72%)
Bear:
(PE: 16.9, Growth: -79.2%)
$0.62
(-76%)
📈
Valuation based on Current Earnings
Trailing PE: 11.17 | Current EPS (TTM): $0.23
Bull Case
$1.41
(-45%)
Analyst growth -50.0%, PE expands to 12.3
Base Case
$1.28
(-50%)
Market implied -50.0%, PE stable at 11.2
Bear Case
$1.75
(-32%)
Severe decline -20.0%, PE contracts to 9.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 23, 2026 6:06 PM ET
Data refreshes hourly during market hours. Next update: 7:06 PM
Data refreshes hourly during market hours. Next update: 7:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 53 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 64 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$686 | 48 HOLD |
|
IMNM
Immunome Inc |
STRONG BUY
16 analysts |
$35 | 59 HOLD |
|
CGON
CG Oncology, Inc. Common… |
STRONG BUY
15 analysts |
$91 | 64 BUY |
